In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

With a team of Ax­o­vant vet­er­ans lead­ing the way, CNS start­up Arvelle Ther­a­peu­tics is near­ing ap­proval for li­censed epilep­sy med cenoba­mate in the EU af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER